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Glutamate levels in the anterior 
cingulate cortex in un-medicated 
first episode psychosis: a proton 
magnetic resonance spectroscopy 
study
Faith R. Borgan  1,2, Sameer Jauhar1, Robert A. McCutcheon  1,2, Fiona S. pepper3, 
Maria Rogdaki1,2, David J. Lythgoe3 & Oliver D. Howes1,2
Converging lines of evidence suggest that glutamatergic dysfunction may contribute to the 
pathophysiology of first episode psychosis. We investigated whether first episode psychosis patients 
free from all pharmacological treatments and illicit substances show cortical glutamatergic alterations. 
One-hundred and eleven volunteers including 65 healthy volunteers and 46 first episode psychosis 
patients free from all pharmacological treatments (28 drug naïve) underwent a proton magnetic 
resonance spectroscopy scan measuring glutamate levels in the bilateral anterior cingulate cortex. 
Symptom severity was measured using the Positive and Negative Syndrome Scale (PANSS) and 
cognition was measured using the Wechsler Adult Intelligence Scale (WAIS) digit symbol test. There 
were no differences in glutamate levels between patients and controls. These findings remained 
unchanged when adjusting for the effects of age, sex and ethnicity or when restricting the analyses 
to patients who were both medication naïve to all pharmacological treatments and illicit substances. 
Whilst these findings do not preclude glutamatergic alterations in psychosis, methodological advances 
are needed for us to investigate whether patients show alterations in other aspects of glutamate 
function, such as pre-synaptic glutamate or release.
Schizophrenia and other psychotic disorders have a lifetime prevalence of approximately 0.7%1,2 and are ranked 
amongst the most disabling health conditions3, with annual costs ranging from 94 million to 102 billion dollars 
for each country, worldwide4. Although pharmacological treatments blocking the D2 dopamine receptor have 
been shown to reduce psychotic symptoms5, they are ineffective for approximately 30% of patients6 and they fail 
to improve cognitive impairments in the illness7. In view of these limitations, further work is needed to identify 
therapeutic mechanisms and biomarkers that may be useful for targeting both psychotic and cognitive symptoms.
Glutamate, the primary excitatory neurotransmitter in the central nervous system8, binds to a number of 
receptors in the brain including the N-methyl-D-aspartate receptor (NMDA), α-amino-3-hydroxy-5-metyl
-4-isoxazolepropionic acid (AMPA) and kainate recepotors8. Converging lines of evidence suggest that glutama-
tergic dysfunction may contribute to the pathophysiology of psychosis9,10.
Glutamate theories of schizophrenia were developed following observations that N-methyl-D-aspartate 
receptor (NMDAR) antagonists induce positive and negative symptoms and cognitive impairments in healthy 
volunteers, paralleling symptoms seen in schizophrenia11–13. In particular, low doses of ketamine, an NMDAR 
antagonist, has been shown to induce psychotic symptoms, cognitive impairments and increase in glutamate 
levels in the anterior cingulate cortex in healthy volunteers14. Since ketamine has also been shown to exacerbate 
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positive symptoms and cognitive impairments in schizophrenia15,16, it has been hypothesized that psychosis may 
be characterised by elevations in cortical glutamate14. However, other studies using comparable doses of ketamine 
have found that ketamine induces psychotic symptoms in healthy volunteers in the absence of any changes in glu-
tamate levels in the anterior cingulate cortex17,18.
Glutamate levels have been investigated in vivo in psychosis using proton magnetic resonance spectroscopy 
(1H-MRS). However, discrepant findings have been reported. While decreased GLX (glutamate + glutamine) 
levels have been reported in the medial prefrontal cortex in 16 antipsychotic-naïve patients with first episode 
psychosis19, other studies have failed to find evidence of glutamate or GLX alterations in the anterior cingulate 
cortex in antipyshcotic-free patients with first episode psychosis20–22. Discrepant findings have also been reported 
in patients with chronic schizophrenia taking antipsychotics, with reports of no differences in GLX in grey mat-
ter23 but decreased glutamate levels in the left24 and bilateral anterior cingulate25. Meta-analyses have also come to 
discrepant conclusions, reporting no differences in glutamate levels in the medial frontal cortex in patients with 
first episode psychosis or chronic schizophrenia26 as well as decreased glutamate levels in the medial prefrontal 
cortex when combining patients with first episode psychosis and chronic schizophrenia27.
Several factors may account for these discrepant findings including illness chronicity and medication use. 
Although previous literature has shown that glutamate levels may alter during the course of illness27 and with the 
use of antipsychotic medication28, few studies19–22 have been conducted in antipsychotic free first episode psy-
chosis patients. The largest study conducted to date, investigated glutamate levels in 45 antipsychotic free and 26 
minimally treated patients in a multi-centre study in a multi-centre study21. However, this study included subjects 
taking compounds shown to influence glutamate levels, including illicit substances (cannabis29 and cocaine30) and 
concurrent treatments (benzodiazepines31 and antidepressants32). Moreover, this study did not to control for the 
potential confound of using three different scanners.
While smaller studies have also been conducted, these studies have used relatively small samples sizes (10–24 
subjects per group)19,20,22 which, whilst well-powered to detect large effect sizes (d > 0.9), lack statistical power 
to detect the moderate effect sizes (d = 0.4–0.6) commonly seen in studies of psychotic disorders33. Moreover, 
many of these studies did not exclude spectra with poor signal-to-noise ratios or metabolite estimates with high 
variability; and they failed to use water suppression or cerebrospinal fluid contamination corrections, which can 
lead to artefacts and problems with spectral fitting34; and they also included some patients currently taking ben-
zodiazepines21,24, shown to influence glutamate levels31,35.
In view of these methodological limitations and that no studies to date have investigated glutamate levels in 
patients with un-medicated first episode psychosis whilst controlling for the potential confounds of illicit sub-
stance use29,30 or concurrent pharmacological treatments that influence glutamate levels31,32, we aimed to inves-
tigate glutamate levels in drug-free first episode psychosis patients within three years of illness onset, excluding 
patients using illicit substances as well as other concurrent pharmacological treatments. In line with the evidence 
discussed above, we hypothesized that glutamate levels would be greater in un-medicated patients with first epi-
sode psychosis relative to healthy volunteers. We also hypothesized that greater glutamate levels in the anterior 
cingulate cortex would be associated with greater levels of symptom severity and poorer cognitive functioning.
Results
Demographics. There were no significant differences in age, sex, ethnicity between patients and controls. 
However, patients relative to controls had fewer years of education following compulsory education (see Table 1). 
Relative to healthy volunteers, patients performed significantly worse on the digit symbol coding test.
Metabolite levels in healthy volunteers acquired on scanner 1 and 2. Paired sample t-tests indi-
cated that there were no statistically significant differences in glutamate estimates acquired on scanner 1 (M = 9.6; 
SD = 1.5) vs. scanner 2 (M = 8.3; SD = 0.9) (t(4) = 2.032, p = 0.112). An intra-class correlation reliability analysis 
indicated that there was good between-scanner reliability, α = 0.642. See Supplementary Materials for scanner 
differences in other metabolites (glutamine, GLX, NAA), spectra linewidth and signal to noise ratios.
Glutamate levels in healthy volunteers and patients wtih first episode psychosis. Datasets 
acquired on scanner 1 and 2 showed a normal pattern of distribution as determined the Kolmogorov-Smirnov 
test. There were no significant differences between patients and controls in linewidth or signal to noise (see 
Supplementary Table 1). One healthy volunteer dataset that had glutamate levels exceeding the Cramér-Rao lower 
bounds ratio was excluded. There was no main effect of group on glutamate levels when adjusting for the effects of 
scanner (F(1,109) = 0.17, p = 0.68), (see Fig. 1), and this remained the case after adjusting for the effects of scan-
ner, age, sex and ethnicity (F(1,83) = 0.15, p = 0.70). There was also no main effect of group on glutamate levels 
when adjusting for the effects of scanner and restricting the analysis to patients who were both medication naïve 
to all pharmacological treatments and free from all illicit substances (F(1,70) = 0.60, p = 0.44) or when restricting 
the analysis to patients diagnosed with schizophrenia who were both medication naïve to all pharmacological 
treatments and free from all illicit substances (F(1,66) = 0.61, p = 0.44). See Supplementary Materials for other 
metabolites. Since there were significant group differences in years of education following compulsory education, 
a post-hoc Pearson’s correlation coefficient was calculated to investigate the association between years of educa-
tion and glutamate levels. There were no significant associations between years of education following compul-
sory education and glutamate levels in either controls (R = 0.05, p = 0.76) or patients (R = −0.15, p = 0.45).
Relationship between metabolite levels and symptom severity. There was no significant associa-
tion between glutamate levels and PANSS total (ß = −1.24, SE = 1.85, p = 0.51, R2 = 0.24), positive (ß = −0.96, 
SE = 0.59, p = 0.11, R2 = 0.22), negative (ß = −0.01, SE = 0.63, p = 0.99, R2 = 0.28) or general PANSS symptom 
severity scores (ß = 0.15, SE = 0.93, p = 0.87, R2 = 0.15), when adjusting for scanner. These findings remained 
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unchanged when controlling for scanner differences, age, sex and ethnicity; and when restricting the analysis 
to patients who were both medication naïve to all pharmacological treatments and not currently using illicit 
substances; or when investigating these relationships separately for each scanner (see Fig. 2 and Supplementary 
Materials for results).
Relationship between metabolite levels and cognition. Healthy volunteers showed no significant 
associations between glutamate levels and cognitive function, as determined by the digit symbol coding test 
(ß = −0.04, SE = 0.30, p = 0.90, R2 = 0.001). Similarly, patients also showed no significant associations between 
glutamate levels and cognitive function, as determined by the digit symbol coding test (ß = −0.16, SE = 0.29, 
p = 0.59, R2 = 0.01). These findings remained unchanged when controlling for scanner differences, age, sex and 
ethnicity; or when restricting the analysis to patients who were both medication naïve and not currently using 
illicit substances; or when investigating these relationships separately for each scanner (see Supplementary 
Materials).
Healthy 
volunteers
First episode 
psychosis t/x2 df p
N 65 46 NA NA NA
Age mean (sd) 25.85 (4.87) 26.18 (4.42) t = −0.357 102 0.722
Sex (male/female) 47/18 38/8 x2 = 1.708 1 0.191
Ethnicity (White Caucassian/Black African or Caribbean/Asian/
mixed/missing data) 24/9/12/3/17 17/11/11/0/7 x
2 = 0.819 1 0.365
Diagnosis (Schizophrenia/Schizoaffective disorder/Bipolar 
Disorder/Psychotic Depression) NA 38/2/4/2 NA NA NA
Global Assessment of Functioning score mean (sd) 94.10 (10.29) 47.71 (17.72) t = 10.901 48 <0.001
WAIS digit symbol coding test score mean (sd) 10.41 (3.02) 8.73 (2.62) t = 2.263 58 0.027
PANSS positive mean (sd) NA 14.33 (7.54) NA NA NA
PANSS negative mean (sd) NA 14.51 (8.46) NA NA NA
PANSS general mean (sd) NA 45.00 (23.41) NA NA NA
PANSS total mean (sd) NA 52.13 (24.50) NA NA NA
Years of education after compulsory education*, mean (sd) 4.36 (1.91) 3.17 (2.42) t = 2.389 74 0.019
Current antipsychotic use (yes/no) 0/65 0/46 NA NA NA
Current benzodiazepine use (yes/no) 0/65 0/46 NA NA NA
Current antidepressant use (yes/no) 0/65 0/46 NA NA NA
Medication naïve (yes/no) NA 26/20 NA NA NA
Table 1. Demographic, clinical and neurochemical measures. *Years of compulsory education in the United 
Kingdom is age 16; NA = not applicable; SD = standard deviation. Group differences between patients and 
controls in demographic variables (age, sex, ethnicity) and clinical characteristics of the patient group.
Figure 1. Anterior cingulate glutamate levels in first episode psychosis and healthy volunteers. Plot showing no 
significant differences in anterior cingulate cortex glutamate levels (ppm) between un-medicated patients with 
first episode psychosis and healthy volunteers (F(1,109) = 0.17, p = 0.68). Group means and standard deviations 
are shown.
4Scientific RepoRts |          (2019) 9:8685  | https://doi.org/10.1038/s41598-019-45018-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
Our main finding was that patients with un-medicated first episode psychosis do not show evidence of glutamate, 
glutamine or GLX abnormalities in the anterior cingulate cortex relative to healthy volunteers. These findings 
remained unchanged when restricting the analysis to patients diagnosed with schizophrenia who were medica-
tion naïve to all pharmacological treatments and not currently taking any illicit substances. We also showed that 
glutamate levels in the anterior cingulate were not linked to symptom severity or cognitive functioning.
Our findings are consistent with literature reporting that antipsychotic naïve patients with first episode psy-
chosis show no differences in glutamate levels in the frontal cortex20–22 and meta-analytic findings showing no 
differences in glutamate levels in the frontal cortex in patients with first episode psychosis26. However, this study 
extends the largest study conducted in un-medicated patients with first episode psychosis21 in three key ways. 
Firstly, we controlled for the effects of scanner differences. Secondly, we excluded subjects taking compounds 
shown to influence glutamate levels including both illicit substances (e.g. cannabis29, cocaine30 and ketamine14) 
and concurrent pharmacological treatments known to influence glutamate levels (e.g. benzodiazepines31 and 
antidepressants32). Thirdly, by scaling metabolites to water as opposed to creatine21, we have avoided the potential 
confound of scaling metabolites to a reference compound that has been shown to be altered in schizophrenia36.
Although our findings are at odds with studies reporting decreased glutamate levels19 and greater glutamine 
levels20, several methodological differences may explain these discrepant findings. Firstly, these prior studies 
Figure 2. Association between anterior cingulate glutamate levels and symptom severity. Plot showing (A) no 
significant association between anterior cingulate glutamate levels (ppm) and PANSS total symptom severity 
scores for scanner 1 (ß = 3.39, SE = 2.95, p = 0.26, R2 = 0.06) or scanner 2 (ß = −3.10, SE = 2.47, p = 0.23, 
R2 = 0.09); (B) no significant association between anterior cingulate glutamate levels and PANSS positive 
symptom severity scores for scanner 1 (ß = 0.48, SE = 0.99, p = 0.63, R2 = 0.01) or scanner 2 (ß = −1.54, 
SE = 0.76, p = 0.06, R2 = 0.21); (C) no significant association between anterior cingulate glutamate levels and 
PANSS negative symptom severity scores for scanner 1 (ß = 0.29, SE = 1.18, p = 0.81, R2 = 0.003) or scanner 2 
(ß = −0.13, SE = 0.76, p = 0.87, R2 = 0.002); (D) no significant association between anterior cingulate glutamate 
levels and PANSS general symptom severity scores for scanner 1 (ß = 2.61, SE = 1.49, p = 0.09, R2 = 0.09) or 
scanner 2 (ß = −0.85, SE = 1.20, p = 0.48, R2 = 0.02).
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included patients currently taking benzodiazepines, shown to influence glutamate levels31,35. Secondly, these 
studies included spectra with poor signal-to-noise ratios and metabolites with high variability estimates ranging 
between 20–75%20,24. These methodological issues could be problematic because standard deviations greater than 
20% introduce error and are typically indicative of poor data quality relating to artefacts arising from motion, 
frequency drift or poor spectral fitting. Moreover, it is unlikely that these studies were statistically powered to 
detect group differences in the context of such high variability since greater sample sizes are needed to detect 
group differences37. However, these discrepancies may also be linked to differences in scanner field strengths, 
voxel placements, imaging acquisition parameters and analytical techniques influencing spectral fitting (e.g. scal-
ing metabolites to water vs. creatine, water suppression parameters and cerebrospinal fluid corrections) which 
may ultimately lead to a large degree in variability across studies. For example, if voxel placement methods differ, 
this will result in the measurement of different brain regions; if cerebrospinal correction methods differ, this will 
lead to the measurement of different tissue types (e.g. grey matter and cerebrospinal fluid vs. grey matter alone).
While we previously reported an inverse association between anterior cingulate cortex glutamate levels and 
positive symptom severity scores38, this study included some patients who had a history of exposure to phar-
macological treatments and recreational illicit substances which, as discussed above, could have influence these 
findings. Our findings are also at odds with reports of a positive association between glutamate levels and total 
symptom severity scores21. The lack of consistency in the literature may be linked to a great deal of heterogene-
ity in proton magnetic spectroscopy measures owing to between-study heterogeneity in sample characteristics, 
imaging acquisition parameters and analytical techniques. The present findings therefore extend the existing 
literature to show that there is no association between anterior cingulate cortex glutamate levels and symptom 
severity scores in first episode psychosis patients diagnosed with schizophrenia who are both free from all phar-
macological treatments and illicit substances, when controlling for the effects of age, sex and ethnicity.
Although a trend level association was observed between glutamate levels and positive symptom severity for 
data acquired using scanner 2, this relationship was not observed in the data acquired on scanner 1 or when com-
bining both datasets. Moreover, although there was a trend level association between glutamate levels and general 
symptom severity scores for data acquired using scanner 1, this was not the case for data acquired on scanner 2 
or when combining both datasets. These findings highlight the need for larger sample sizes to be used in order to 
avoid the risk of type II error37.
strengths and Limitations
A strength of the study was that no participants had been taking any compounds acting on the central nervous 
system, including pharmacological treatments or illicit substances. While we cannot exclude the possibility that 
the prior use of antipsychotics may have influenced the results, patients had a minimum drug washout period of 
6 weeks and no patients had previously taken depot medications. Moreover, while we cannot exclude the possi-
bility that prior illicit substance use may have influenced our findings, patients had negative urine drug screens 
prior to their scans on tests that able to detect cannabis, cocaine, amphetamine and opiate use and we excluded 
subjects with a history of substance use or dependence. Prior substance use is therefore unlikely to be a significant 
confound.
A methodological limitation of proton magnetic resonance spectroscopy is that it is not possible to distin-
guish between intra-cellular and extra-cellular glutamate levels or examine multiple brain regions simultane-
ously using the sequences that we used. Another limitation of this method is that it is not possible to correct for 
subject motion. This is a problem because scan to scan variations in phase and frequency of metabolite signals 
may result in incoherent averaging across frames, leading to reduced signal-to-noise39. A strength of the present 
investigation was that we used water suppression during imaging acquisition. Failure to use water suppression 
during imaging acquisition leads to a large water peak which may cause problems with spectral fitting39. While we 
cannot exclude the possibility that relaxation times may be different between patients and controls in the anterior 
cingulate cortex, future studies are needed to investigate this in order for us to identify if this needs to be taken 
into consideration in the analysis.
While the digit symbol coding test is highly correlated with global cognitive impairments, determined by 
comprehensive neuropsychological tests measuring attention, processing speed, executive function and working 
memory40,41, this measure lacks specificity at the expense of sensitivity and it is therefore unclear which precise 
aspect of cognition is affected. This measure was chosen to minimise subject burden, but, given our findings, it 
would be useful to determine if glutamate levels are linked to specific aspects of cognitive function in further 
studies. While we cannot exclude the possibility that our findings may have been influenced by group differences 
in years of education, this variable was not associated with glutamate levels in patients or controls and it is there-
fore unlikely to be a major confound.
A limitation of the study was that the data were acquired on two different scanners exhibiting different 
signal-to-noise ratios. Since we controlled for scanner differences in all analyses, a similar number of patients and 
controls were acquired on both scanners and we discarded spectra with poor signal-to-noise ratios, the use of 
different scanners is unlikely to influence the results. Moreover, our test-retest findings indicated that there were 
no significant differences between scanners for glutamate, glutamine or GLX estimates, supporting the integra-
tion these datasets.
Future studies using 7-Tesla scanners are needed to improve the quantification of metabolites and to improve 
signal-to-noise ratios. Previous literature has reported a 2.8-fold increase in signal-to-noise ratios and a sig-
nificant decrease in the variability of metabolite estimates acquired on a 7-Tessla scanner relative to a 3-Tessla 
scanner42. These methodological advances will improve the validity and reliability of metabolite measurement 
and also enable us to estimate metabolites present at lower concentrations in the brain42,43. Preliminary stud-
ies using 7-Tesla scanners have shown that glutamate levels are lower in the dorsal anterior cingulate cortex in 
antipsychotic-treated patients with first episode psychosis relative to controls44 and that glutamate, glutamine and 
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glutathione levels are lower in the anterior cingulate cortex in antipsychotic-treated patients with residual schiz-
ophrenia relative to controls45. However, future studies are needed to confirm this first episode psychosis without 
the confounds of medication or substance use.
Implications
Glutamate metabolite estimates acquired using proton magnetic resonance spectroscopy reflect the average signal 
of intra-cellular and extra-cellular glutamate levels within a particular brain region46. In view of the limited spa-
tial resolution of proton magnetic resonance spectroscopy, our finding that there were no significant  differences 
between patients and healthy volunteers does not exclude the possibility that there may be alterations in the cor-
tical pre-synaptic synthesis of glutamate or glutamate release.
Since proton magnetic resonance spectroscopy provides the average signal of metabolites across all frames 
when subjects are at rest, motion artefacts that may influence metabolite fitting cannot be removed. In view of 
these limitations and that glutamatergic functioning is involved in the dynamic modulation of synaptic connec-
tions thought to underlie learning and memory47,48, our findings do not exclude the possibility that patients with 
first episode psychosis may show dynamic alterations in the glutamate system, involved in synaptic plasticity.
Our finding that patients and controls do not show differences in glutamate levels also does not exclude the 
possibility of NMDAR dysfunction in first episode psychosis. Future studies are needed to identify whether 
patients show NMDAR alterations and how such alterations might be linked to glutamatergic function. Since 
many of the patients included in the present investigation were medication naïve, it was not possible for us to 
stratify the sample according to treatment response. Since previous literature has shown that treatment resistant 
patients show greater glutamate levels relative to treatment responsive patients49, future longitudinal studies are 
needed to investigate the developmental trajectory of glutamatergic alterations in first episode psychosis, and 
how this relates to treatment response. It should also be noted that these findings do not preclude glutamatergic 
alterations in other brain regions50–52.
Conclusions
We showed evidence for the first time, as far as we’re aware, that patients with first episode psychosis who are 
free from all pharmacological treatments and illicit substances, do not show glutamate alterations in the bilateral 
anterior cingulate cortex relative to healthy volunteers. Future studies are needed to investigate whether patients 
show glutamate alterations in other brain regions implicated in the pathophysiology of psychosis. Methodological 
advances are also needed to enable the investigation of the pre-synaptic synthesis of glutamate and glutamate 
release in schizophrenia.
Methods
ethics statement. Ethical approvals were obtained from the local NHS Research Ethics Committees to con-
duct the study (Camberwell St. Giles, 14/LO/1289; Cambridge East, 12/EE/0220). The study adhered to the study 
protocol and guidelines described by the Declaration of Helsinki. Informed, written consent was obtained from 
all subjects.
Subjects. A total of 111 volunteers (65 healthy volunteers, 46 un-medicated first episode psychosis patients) 
were recruited. All patients were recruited from the first episode psychosis services at South London Maudsley 
NHS Foundation Trust and the West London Mental Health NHS Trust. Age (age +/− 3 years) and sex-matched 
healthy volunteers were recruited via local advertising. Since two scanners were used for the study, an additional 
5 healthy volunteers were recruited and scanned on two different scanners in order to determine inter-scanner 
variability. Data will be made available upon request.
Inclusion/exclusion criteria. Volunteers were aged 18–35 and were able to give informed written consent. 
Volunteers were excluded if they had: 1) a history of a head injury leading to loss of consciousness, 2) personal 
or family history of neurological or physical health problems, 3) contraindications to MRI safety including head 
trauma, pregnancy, the presence of metal plates, pins, bridges or dentures; or 4) current history of substance use 
or dependence as determined by the Structured Clinical Interview for DSM-IV-TR (SCID-I/P)53.
First episode psychosis patients met following inclusion criteria: (1) diagnosis of a psychotic disorder as deter-
mined by the ICD-10; (2) antipsychotic naïve or antipsychotic free for at least 6 weeks, as determined by medical 
records and self-report; (3) no current use of any concurrent pharmacological treatments as determined by medi-
cal records and self-report (e.g. benzodiazepines, antidepressants etc.); (4) illness duration of less than three years 
as determined by medical records and self-report. Healthy volunteers met the additional inclusion criteria includ-
ing: (1) no current or lifetime history of an Axis-I disorder as determined by the Structured Clinical Interview for 
DSM-IV-TR (SCID-I/P)53 and (2) no family history of an Axis-I disorder in first and second-degree relatives as 
determined by the Family Inventory for Genetics studies (FIGS)54.
Demographics. Age, sex, ethnicity and years of education were recorded.
Clinical measures. Clinical symptom severity was determined by trained staff using the Positive and 
Negative Syndrome scale (PANSS)55. Social and occupational functioning was measured using the Global 
Assessment of Functioning (GAF)56. Healthy volunteers were screened for personal and family history of men-
tal health problems using SCID-I/P53 and FIGS54, respectively. Cognitive functioning was assessed using the 
Wechsler digit symbol coding test57. This was chosen based on previous findings that it is highly correlated with 
overall cognitive impairments in FEP as determined by comprehensive neuropsychological tests for attention, 
processing speed, executive function and working memory40,41.
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Neuroimaging. All 111 volunteers underwent an MRI scan at the Centre for Neuroimaging Sciences at 
King’s College London. Sixty-one scans (33 controls and 28 patients) were acquired using the General Electric 
MR750 3.0 T MRI scanner (scanner 1). Fifty scans (32 controls, 18 patients) were acquired on the General Electric 
(GE, Milwaukee, Wisconsin, USA) Signa HDxt 3.0 T MRI scanner (scanner 2). The dataset acquired on scanner 2 
formed part of a larger study investigating the relationship between glutamate and dopamine38. While the afore-
mentioned manuscript included 28 patients, only 17 of these patients met the inclusion criteria for the present 
study. An additional 5 healthy volunteers were scanned on both scanners to validate the integration of datasets 
acquired on different scanners.
Neuroimaging acquisition. The neuroimaging acquisition parameters for scanner 1 and 2 were as fol-
lows: internal localizer scans were used to determine the anterior commissure-posterior commissure line and 
inter-hemispheric angle. For the voxel placements, 3D coronal inversion recovery prepared spoiled gradient echo 
(IR-SPGR) scans were acquired, followed by auto pre-scans for optimisation of water suppression and shimming. 
1H-MRS spectra were acquired for the anterior cingulate region-of-interest (right-left 20 mm × anterior-posterior 
20 mm × superior-inferior 20 mm). The placement of the anterior cingulate voxel was based on the midline sagit-
tal localizer with the centre of the 20 mm × 20 mm × 20 mm voxel placed 13 mm above the anterior portion of the 
genu of the corpus callosum, perpendicular to the anterior commissure-posterior commissure line to minimize 
the inclusion of white matter and cerebral spinal fluid (CSF) (see Supplementary Fig. 1 for images of the coronal, 
axial and sagittal placement of the voxel). Finally, the 1H-MRS spectra (Point RESolves Spectroscopy (PRESS), 
TE = 30 ms, TR = 2 s) were obtained through the PROton Brain Examination (PROBE) sequence by GE, which 
includes water suppression.
Neuroimaging analysis. The neuroimaging analysis methods for scanner 1 and 2 were as follows: 
water-scaled metabolites were analysed using LC-model 6.3-0I- using an experimentally acquired basis set to 
estimate concentrations of  16 metabolites including glutamate, glutamine, GLX (glutamate + glutamine), 
N-Acetyl-Aspartate (NAA), L-alanine, aspartate, creatine, phosphocreatine, GABA, glucose, glycerophosphocho-
line, glycine, myo-inositol, L-lactate, N-acetylaspartylglutamate, phosphocholine and taurine. We report metab-
olite values scaled to water, as opposed to creatine, based on previous literature indicating that creatine levels are 
lower in patients with schizophrenia relative to healthy volunteers36. Metabolite analyses were restricted to spectra 
with linewidth (full-width at half-maximum; FWHM) ≤ 0.1 ppm, Cramér-Rao lower bounds (CRLB) for gluta-
mate ≤20%, signal to noise ratio ≥5. In-house scripts written in Python were used to identify the relative distri-
bution of white matter, grey matter and cerebrospinal fluid in the 8 cm3 voxel prescribed to the anterior cingulate. 
The following correction was subsequently applied in order to correct for cerebrospinal fluid within the 20 mm3 
voxel, where M = raw metabolite value, WM = white matter and GM = grey matter, as described previously58. In 
the equation, the numerator accounts for the fraction of each tissue type within the voxel, corrected by the water 
concentration in the tissue type. Since the initial LC model analysis was run assuming the voxel was pure white 
matter, the numerator is divided by the concentration of water in white matter. The denominator corrects for the 
assumption CSF doesn’t contain metabolites. No correction was applied for relaxation times, except for assuming 
the tissue water T2 = 80 ms. The equation also includes a correction for the default assumption the voxel is pure 
WM during the LCModel analysis.
=
+ × . + × .
+
Mcorr M WM GM CSF
WM GM
( ( 1 22) ( 1 55)
( )
)
Statistical analyses. All statistical analyses were conducted using the Statistical Package for the Social 
Sciences (SPSS; Version 22). Normality of distribution was assessed using the Kolmogorov-Smirnov test. The 
significance threshold was p < 0.05 for all statistical tests and tests were two-tailed. Bonferroni corrections for 
multiple comparisons were used in cases where there was a statistically significant difference between groups, 
p < 0.05 (two-tailed).
Paired-samples t-tests were used to investigate differences in metabolite estimates, spectra linewidth, spectra 
standard deviations and signal to noise for 5 subjects who were scanned on both scanner 1 and 2. An intra-class 
correlation reliability analysis (ICC) was conducted in order to determine the reliability of metabolite levels esti-
mates acquired on scanner 1 and 2.
A one-way analyses of covariance (ANCOVA) was conducted to determine whether there were differences in 
glutamate levels between patients and controls, when controlling for scanner differences. Secondary ANCOVAs 
were conducted to determine whether there were differences in other metabolite levels (glutamine, GLX and 
NAA) between patients and controls. Given the effects of age59, sex25 and ethnicity60 on metabolite levels, a 
one-way ANCOVA was also conducted to determine whether there were differences in metabolite levels between 
patients and controls when controlling for scanner differences, age, sex and ethnicity. Secondary ANCOVAs 
were also conducted to determine if there were differences in metabolite levels between patients and controls, 
adjusting for scanner differences, when restricting the analysis to 1) patients who were both medication naïve to 
all pharmacological treatments and free from all illicit substances; and when restricting the analysis to 2) patients 
satisfying the diagnostic criteria for schizophrenia who are both medication naïve to all pharmacological treat-
ments and free from all illicit substances.
Multiple linear regressions were used to determine the relationship between glutamate levels and positive, 
negative, general and total symptom severity. A multiple linear regression model was used including glutamate 
levels and scanner as the independent variable and PANSS symptom severity scores as the dependent var-
iable. Secondary multiple linear regressions were also conducted including scanner, age, sex and ethnicity as 
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independent variables. Given the effects of antipsychotic medication61 and illicit substance use29,30 on metabolite 
levels, these analyses were repeated when restricting the analysis to patients who were medication naïve and also 
free from all illicit substances, adjusting for scanner. All of these analyses were repeated separately for datasets 
acquired on each scanner.
A multiple linear regression was used to determine the relationship between glutamate levels and cognitive 
function, as determined by the digit symbol coding test, separately for controls and patients. These linear regres-
sion models included glutamate and scanner as the independent variables and the cognitive tests as the dependent 
variable. Secondary multiple linear regressions were also conducted to determine the relationship between gluta-
mate levels and cognitive function, when controlling for scanner differences, age, sex and ethnicity by including 
glutamate, scanner, age, sex and ethnicity as independent variables and the cognitive test scores as the dependent 
variable. Given the effects of antipsychotic medication61 and illicit substance use29,30 on metabolite levels, these 
analyses were repeated when restricting the analysis to patients who were medication naïve and also free from all 
illicit substances, adjusting for scanner. All of these analyses were also repeated separately for datasets acquired 
on each scanner. Since we observed group differences in years of education, following compulsory education, 
post-hoc Pearson’s correlation coefficients were calculated to investigate the association between glutamate levels 
and years of education, in each group.
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